A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF10073 After Single and Multiple Ascending Doses in Healthy Volunteers Via Inhalation
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs CHF 10073 (Primary)
- Indications Pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Chiesi Farmaceutici SpA
- 24 Jan 2025 Status changed from not yet recruiting to recruiting.
- 02 Jan 2025 New trial record